Search

Displaying results 801 - 810 of 9689 in total
  1. Drug

    Trichlormethiazide

    go.drugbank.com/drugs/DB01021
    ApprovedVet approved

    A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830)

  2. Drug

    Elagolix

    go.drugbank.com/drugs/DB11979
    ApprovedInvestigational

    Moreover, women who are affected by this condition can suffer for up to six to ten years and visit multiple physicians before receiving a proper diagnosis [A35868, A35869, F801].

  3. Drug

    Remestemcel-L

    go.drugbank.com/drugs/DB13973
    ApprovedInvestigationalWithdrawn

    Remestemcel-L is a third-party, off-the-shelf suspension of ex-vivo cultured adult human mesenchymal stem cells intended for intravenous infusion. … Based on its tolerability and safety profile, remestemcel-L is a promising alternative to second-line immunosuppressive agents [A31818].

    Synonyms: Remestemcel-L
  4. Drug

    Antithrombin III human

    go.drugbank.com/drugs/DB11598
    ApprovedInvestigational

    A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.

  5. Drug

    Lusutrombopag

    go.drugbank.com/drugs/DB13125
    ApprovedInvestigational

    x 10^9/L were administered lusutrombopag orally [L4166]. … TPOR is a regulatory target site for endogenous thrombopoietin, which acts as a primary cytokine to promote megakaryocyte proliferation and differentiation, and affect other hematopoietic lineages as well

  6. Drug

    Ziprasidone

    go.drugbank.com/drugs/DB00246
    ApprovedInvestigational

    [A180748] Although ziprasidone is classified as an atypical antipsychotic, it appears to have a lower incidence of metabolic adverse effects compared to other medications in the same class.[A190525]

    Products: ZIPRASIDON AL 20MG HKP, ZIPRASIDON AL 40MG HKP
  7. Drug

    Anagrelide

    go.drugbank.com/drugs/DB00261
    ApprovedInvestigational

    Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. … [A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated.[A214274]

    Categories: Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexProducts: ANAGRELID AL 0.5MG HKP
  8. Drug

    Pitavastatin

    go.drugbank.com/drugs/DB08860
    ApprovedInvestigational

    events (heart attack, stroke, coronary revascularization, and coronary death) for every 1 mmol/L reduction in LDL without any significant side effects or risks. … [A181087, A181406] Evidence has shown that even for low-risk individuals (with <10% risk of a major vascular event occurring within 5 years) statins cause a 20%-22% relative reduction in major cardiovascular

  9. Drug

    Black cohosh

    go.drugbank.com/drugs/DB13975
    ApprovedInvestigational

    [A32542] Results from studies suggest that C. racemosa possesses a central activity instead of a hormonal effect. … Black cohosh (_Actaea racemosa_ or _Cimicifuga racemosa_), a member of the buttercup family, is a perennial plant which native to North America.

  10. Drug

    NNC-55-0396 free base

    go.drugbank.com/drugs/DB17037
    Experimental

    NNC-55-0396 is a T-type Ca(2+) channel inhibitor.[A253047]